相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Long-term-survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer (vol 17, pg v118, 2006)
Hans von der Maase et al.
ANNALS OF ONCOLOGY (2011)
Clinical cancer advances 2007: Major research advances in cancer treatment, prevention, and screening - A report from the American Society of Clinical Oncology
Julie Gralow et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Gemcitabine and paclitaxel chemotherapy as a second-line treatment for advanced or metastatic urothelial carcinoma
Kazumasa Matsumoto et al.
INTERNATIONAL JOURNAL OF UROLOGY (2007)
Weekly paclitaxel and carboplatin against advanced transitional cell cancer after failure of a platinum-based regimen
Tsutomu Kouno et al.
EUROPEAN UROLOGY (2007)
Paclitaxel Carboplatin chemotherapy as a second-line chemotherapy for advanced platinum resistant urothelial cancer in Japanese cases
Norihito Soga et al.
INTERNATIONAL JOURNAL OF UROLOGY (2007)
Gemcitabine and ifosfamide as a second-line treatment for cisplatin-refractory metastatic urothelial carcinoma: a phase II study
Chia-Chi Lin et al.
ANTI-CANCER DRUGS (2007)
A phase II study of PS-341 (Bortezomib) in advanced or metastatic urothelial cancer. A trial of the Princess Margaret Hospital and University of Chicago phase II consortia
Gonzalo Gomez-Abuin et al.
INVESTIGATIONAL NEW DRUGS (2007)
Efficacy and safety of gemcitabine monotherapy in patients with transitional cell carcinoma after cisplatin-containing therapy: A japanese experience
Hideyuki Akaza et al.
JAPANESE JOURNAL OF CLINICAL ONCOLOGY (2007)
Paclitaxel with cisplatin as salvage treatment for patients with previously treated advanced transitional cell carcinoma of the urothelial tract
Ji Eun Uhm et al.
NEOPLASIA (2007)
Salvage chemotherapy with paclitaxel, ifosfamide, and nedaplatin in patients with urothelial cancer who had received prior cisplatin-based therapy
Nobuo Shinohara et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2006)
Phase II study of pemetrexed for second-line treatment of transitional cell cancer of the urothelium
Christopher J. Sweeney et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
A phase II study of vinflunine in bladder cancer patients progressing after first-line platinum-containing regimen
S. Culine et al.
BRITISH JOURNAL OF CANCER (2006)
Biweekly paclitaxel and gemcitabine for patients with advanced urothelial cancer ineligible for cisplatin-based regimen
T Takahashi et al.
JAPANESE JOURNAL OF CLINICAL ONCOLOGY (2006)
Long-term-survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer
H von der Maase et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Weekly paclitaxel and gemcitabine in advanced transitional-cell carcinoma of the urothelium: A phase II Hoosier Oncology Group Study
JX Li et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Alcohol, IgE and allergy
A Gonzalez-Quintela et al.
ADDICTION BIOLOGY (2004)
Cisplatin, gemcitabine, and ifosfamide as weekly therapy: A feasibility and phase II study of salvage treatment for advanced transitional-cell carcinoma
LC Pagliaro et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
Phase II trial of weekly paclitaxel in patients with previously treated advanced urothelial cancer
DJ Vaughn et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
Gemcitabine monotherapy as second-line treatment in cisplatin-refractory transitional cell carcinoma -: Prognostic factors for response and improvement of quality of life
P Albers et al.
ONKOLOGIE (2002)
Combination chemotherapy with gemcitabine and ifosfamide as second-line treatment in metastatic urothelial cancer. A phase II trial conducted by the Hellenic Cooperative Oncology Group
D Pectasides et al.
ANNALS OF ONCOLOGY (2001)
Docetaxel and ifosfamide as second line treatment for patients with advanced or metastatic urothelial cancer after failure of platinum chemotherapy: A phase 2 study
S Krege et al.
JOURNAL OF UROLOGY (2001)
Phase II EORTC trial with 5-fluorouracil, cisplatin and interferon-α as second-line treatment of advanced transitional cell cancer of the urothelial tract
PHM De Mulder et al.
ANNALS OF ONCOLOGY (2000)
分享论文
